Twenty‐four‐hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole

Abstract

SUMMARY Simultaneous 24‐hour intragastric acidity and plasma gastrin concentrations were measured in 12 duodenal ulcer patients before and on the twenty‐eighth day of treatment with either ranitidine 150 mg b.d. or omeprazole 20 mg o.m. Median integrated 24‐hour intragastric acidity was decreased significantly from 1148 to 490 and 36 mmol. hour litre−1 during treatment with ranitidine and omeprazole, respectively, whilst median intragastric 24‐hour plasma gastrin was raised significantly from 328 to 799 and 1519 pmol. hour litre−1 respectively. When the results of all 48 experiments were considered together, there was a significant inverse correlation between the 24‐hour integrated values for intragastric acidity and plasma gastrin concentration. Both drugs caused a significant elevation of plasma gastrin throughout the 24 hours, although ranitidine had no effect on intragastric acidity from 1900 to 2200 hours. When compared with similar profiles of acidity and gastrin in pernicious‐anaemia patients, the modest elevations of plasma gastrin observed in this study suggest that neither drug will be associated with clinically relevant enterochromaffin‐like cell proliferation in duodenal ulcer patients.

Withdrawing PPI Therapy After Healing Esophagitis Does Not Worsen Symptoms or Cause Persistent Hypergastrinemia: Analysis of Dexlansoprazole MR Clinical Trial Data

“…The changes from baseline to day −1 of maintenance trials ( n =207), to maintenance month 1 ( n =130), and to maintenance month 3 ( n =52) were 85.5 (120.8) pg/ml, 3.5 (42.3) pg/ml, and 3.2 (66.8) pg/ml, respectively. As would be expected, gastrin values did increase from baseline to day −1 of the maintenance studies while patients were receiving active treatment (18,19). In patients randomized to placebo, mean gastrin values at months 1 and 3 were essentially unchanged from baseline.…”

Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies

“…In particular, several mechanisms suggesting a biological link between use of the proton pump inhibitor and gastrointestinal tumor risk, including colorectal cancer, are proposed. First, the proton pump inhibitor induces hypergastrinaemia,27,28) and long-term exposure of elevated serum gastrin could promote neoplastic growth in areas such as the stomach or colon 4-7). Second, chronic suppression of gastric acid secretion may lead to enteric bacterial overgrowth in intestine, which could produce carcinogens including nitrosamines and might increase the risk of colorectal cancer 25)…”

In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats

“…Drug interactions are also not common among them (40). Furthermore, H 2 blockers inhibit nocturnal acid secretion that depends largely on histamine as well (41). There are different therapeutic strategies for refractory GERD, such as changing the usage of PPIs to twice a day, adding bedtime H 2 blockers to the PPI regimen or using high doses of PPI or H 2 blockers.…”